Botulinum Toxin Type E is a botulinum neurotoxin serotype E indicated for temporary improvement of moderate to severe glabellar lines in adults, producing rapid-onset, short-duration chemical denervation through SNAP-25 cleavage. It blocks neuromuscular transmission by cleaving SNAP-25, producing partial chemical denervation and a localized reduction in muscle activity.
- Mechanism
- Curator reviewed · 5 references
TrenibotulinumtoxinE blocks neuromuscular transmission. After intramuscular injection, the toxin binds rapidly to specific cell surface receptors on motor nerve terminals and is transported across the plasma membrane by receptor-mediated endocytosis. The proteolytic light chain is released into the cytosol, where it cleaves SNAP-25, a presynaptic protein required for the vesicle docking and fusion that underlies acetylcholine release. Disruption of SNAP-25 inhibits acetylcholine release from nerve terminals, producing partial chemical denervation and a localized reduction in muscle activity. The short intracellular half-life of the serotype E light chain underlies the rapid onset and short duration of effect.
- Primary indication
- TrenibotulinumtoxinE is indicated for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines), when these have an important psychological impact, in adult patients.Curator reviewed · 1 structured indication
- First approval
- Canada, 2026
- Also known as
- BONTOXILYSIN-E · Botulinum neurotoxin serotype E · BOTULINUM NEUROTOXIN SEROTYPE E (BONT/E) (EB-001) · BOTULINUM NEUROTOXIN TYPE E
- Code names
- EB-001
Resolves to
What you can answer from here — as of September 14, 2026
Which drugs share a target with Botulinum Toxin Type E, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account